Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors: New among Antidiabetic Drugs
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors: New among Antidiabetic Drugs
Authors
Keywords
Antidiabetic drugs, Renal glucose uptake, Ascending tubule, Sodium-glucose Co-transporter 2
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 28, Issue 4, Pages 331-334
Publisher
Springer Nature
Online
2014-05-13
DOI
10.1007/s10557-014-6522-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III Study
- (2014) Linong Ji et al. CLINICAL THERAPEUTICS
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
- (2013) Wendy L. Bennett et al. ANNALS OF INTERNAL MEDICINE
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Ipragliflozin Does Not Prolong QTc Interval in Healthy Male and Female Subjects: A Phase I Study
- (2013) Wenhui Zhang et al. CLINICAL THERAPEUTICS
- Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis
- (2013) S. Goring et al. DIABETES OBESITY & METABOLISM
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2013) EUROPEAN HEART JOURNAL
- Urinary tract infections in patients with diabetes treated with dapagliflozin
- (2013) Kristina M. Johnsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effects of Dapagliflozin on Cardiovascular Risk Factors
- (2013) Agata Ptaszynska et al. POSTGRADUATE MEDICINE
- Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients
- (2013) Young Ki Lee et al. Diabetes & Metabolism Journal
- Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
- (2012) Sreeneeranj Kasichayanula et al. ADVANCES IN THERAPY
- No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects
- (2012) R. A. Smulders et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2012) K. Stenlöf et al. DIABETES OBESITY & METABOLISM
- Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
- (2011) Kathleen R. Richard et al. CLINICAL THERAPEUTICS
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
- (2011) Glenn F. Carlson et al. Diabetes Therapy
- Controversies in the cardiovascular management of type 2 diabetes
- (2010) L. H. Opie et al. HEART
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now